%0 Journal Article
%T Incretins and the specific mechanism of action of liraglutide, the first applicable human glucagon-like peptide 1 analog in the treatment of type 2 diabetes
%A Edoardo Mannucci
%A Caterina Lamanna
%J Journal of Receptor, Ligand and Channel Research
%D 2010
%I 
%X Edoardo Mannucci, Caterina LamannaDiabetes Agency, Careggi Teaching Hospital, Florence, ItalyAbstract: Liraglutide is a once-daily glucagon-like peptide 1 (GLP-1) receptor agonist, approved for use as a treatment of type 2 diabetes. Like other drugs of the same class, liraglutide stimulates insulin secretion in a glucose-dependent fashion, has the potential of preventing ¦Â-cell mass decline, and inhibits food intake. In addition, experimental studies suggest that the GLP-1 receptor agonists could protect myocardium from ischemic injury, enhancing cardiac function. In clinical trials, liraglutide (in monotherapy or as add-on to 1 or 2 oral drugs) is as effective as, or more effective than, other agents (sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, insulin, and exenatide) in reducing hemoglobin A1c; induces weight loss; and has a blood pressure-lowering effect. The possible beneficial cardiovascular effects need to be confirmed by specifically designed long-term studies.Keywords: liraglutide, type 2 diabetes, GLP-1 receptor agonist
%U http://www.dovepress.com/incretins-and-the-specific-mechanism-of-action-of-liraglutide-the-firs-a5361